Commissioning of molecular genetic tests for cancer

This Stakeholder Briefing has been developed to clarify the new arrangements for commissioning and funding of six molecular diagnostic tests for cancer in the NHS in England for 2016/17. It aims to provide NHS staff – be they commissioner or hospital provider financial staff, clinicians and pathology staff – with a clear understanding how the new funding arrangements for these tests in 2016/17 will operate to support timely and appropriate patient access. This Briefing has been prepared by the The Association of the British Pharmaceutical Industry (ABPI), The British In Vitro Diagnostics Association (BIVDA) and Cancer Research UK (CRUK) with the support of the NHS England Specialised Commissioning Team.